Journal article

Ex-vivo alpha-Galactosylceramide activation of NKT cells in humans and macaques

Caroline S Fernandez, Garth Cameron, Dale I Godfrey, Stephen J Kent

JOURNAL OF IMMUNOLOGICAL METHODS | ELSEVIER SCIENCE BV | Published : 2012

Abstract

NKT cells are key mediators of antiviral and anticancer immunity. Experiments in mice have demonstrated that activation of NKT cells in vivo induces the expression of multiple effector molecules critical to successful immunity. Human clinical trials have shown similar responses, although in vivo activation of NKT cells in humans or primate models are far more limited in number and scope. Measuring ex vivo activation of NKT cells by the CD1d-restricted glycolipid ligand α-Galactosylceramide (α-GalCer) through cytokine expression profiles is a useful marker of NKT cell function, but for reasons that are unclear, this approach does not appear to work as well in humans and non-human primate maca..

View full abstract

Grants

Awarded by Australian National Health and Medical Research (NHMRC)


Awarded by NHMRC


Funding Acknowledgements

We thank Wendy Winnall, Konstantinos Kyparissoudis, Angela Chan, Sheilajen Alcantara, Pradeep Sidana, and Megan Schepers for expert assistance and advice. This research was supported by Australian National Health and Medical Research (NHMRC) awards 510448, 629000 and 454569. GC is supported by a Cancer Research Institute postgraduate scholarship. DIG is supported by an NHMRC research fellowship 454309; SJK is supported by an NHMRC research fellowship 508937.